Although there is conflicting evidence regarding the temporal staging of AD biomarkers and cognitive symptoms (Braak et al., 2011; Jack et al., 2013; Edmonds et al., 2015b; Veitch et al., 2019; Elman et al., 2020), it is likely that in most cases abnormal levels of amyloid beta are first reached, followed by abnormal levels of tau, which in turn affect cognition (Dubois et al., 2016; Jack et al., 2017, 2018). The gene discussed is MAPT; the disease is Alzheimer disease.